laronidase
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie's Syndrome
Trial Timeline
Jul 1, 2004 → May 1, 2007
NCT ID
NCT00144768About laronidase
laronidase is a approved stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT00144768. Target conditions include Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome.
What happened to similar drugs?
4 of 14 similar drugs in Mucopolysaccharidosis I were approved
Approved (4) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05134571 | Approved | Completed |
| NCT00418821 | Approved | Terminated |
| NCT00144768 | Approved | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I